Vertex Pharmaceuticals Overview

  • Founded
  • 1989
Founded
  • Status
  • Public
  • Employees
  • 3,900
Employees
  • Stock Symbol
  • VRTX
Stock Symbol
  • Investments
  • 15
  • Share Price
  • $254.17
  • (As of Monday Closing)

Vertex Pharmaceuticals General Information

Description

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Contact Information

Website
www.vrtx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 50 Northern Avenue
  • Boston, MA 02210
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vertex Pharmaceuticals Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$254.17 $246.72 $176.36 - $292.75 $63.1B 256M 1.65M $9.57

Vertex Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 59,846,079 49,749,641 55,852,812 52,911,110
Revenue 7,947,595 7,574,400 6,205,700 4,162,800
EBITDA 3,052,627 2,912,600 3,262,400 1,496,600
Net Income 2,451,062 2,342,100 2,711,700 1,176,800
Total Assets 14,256,100 13,432,500 11,751,800 8,318,465
Total Debt 872,500 934,100 931,900 661,662
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vertex Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vertex Pharmaceuticals‘s full profile, request access.

Request a free trial

Vertex Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatm
Drug Discovery
Boston, MA
3,900 As of 2021
00.000
000 0000-00-00
000000&0

000000 0

um dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qu
0000 000000000
Menlo Park, CA
00 As of 0000
00000
00000000 00000

000000 0

illum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vertex Pharmaceuticals Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adicet Bio Formerly VC-backed Menlo Park, CA 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000 00000000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000000 00000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
0000000 0000000000 Formerly VC-backed Waltham, MA 0 00000 000000000 00000
You’re viewing 5 of 37 competitors. Get the full list »

Vertex Pharmaceuticals Patents

Vertex Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210275496-A1 Methods of treating apol-1 dependent focal segmental glomerulosclerosis Pending 06-Mar-2020 000000000
US-20210246121-A1 Solid forms of apol1 inhibitor and methods of using same Pending 04-Feb-2020 0000000000
US-20210260036-A1 Methods of treatment for alpha-1 antitrypsin deficiency Pending 30-Jan-2020 00000000000
US-20210198241-A1 Substituted tetrahydrofurans as modulators of sodium channels Pending 06-Dec-2019 0000000000
US-20210047350-A1 Modulators of cystic fibrosis transmembrane conductance regulator Pending 14-Aug-2019 C07F7/0816
To view Vertex Pharmaceuticals’s complete patent history, request access »

Vertex Pharmaceuticals Executive Team (37)

Name Title Board Seat Contact Info
Reshma Kewalramani MD Chief Executive Officer, President & Board Member
Charles Wagner Jr. Chief Financial Officer, Finance & Executive Vice President
Stuart Arbuckle Executive Vice President and Chief Operating Officer
Stephanie Franklin Chief Human Resources Officer & Senior Vice President
Mike Tirozzi Chief Information & Data Officer & Senior Vice President
You’re viewing 5 of 37 executive team members. Get the full list »

Vertex Pharmaceuticals Board Members (19)

Name Representing Role Since
Alan Garber Ph.D Self Board Member and Member of Audit and Finance Committee and Scientific and Technology Committee 000 0000
Bruce Sachs Self Lead Independent Director and Chairman of Corporate Governance and Nominating Committee and Management Development and Compensation Committee 000 0000
Diana McKenzie Vertex Pharmaceuticals Board Member 000 0000
Jeffrey Leiden Ph.D Vertex Pharmaceuticals Executive Chairman 000 0000
Lloyd Carney Ph.D Self Board Member and Member of Audit and Finance Committee 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Vertex Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vertex Pharmaceuticals Investments & Acquisitions (15)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 09-Nov-2021 00000 0000 00000 Drug Discovery
00000000 12-Oct-2021 00000 0000 000.00 Drug Discovery 00000 000
00000000 0000 09-Sep-2021 00000 0000 00000 Drug Discovery
000000 000000 11-Mar-2020 00000 0000 00000 Biotechnology
Semma Therapeutics 10-Oct-2019 Merger/Acquisition 00000 Drug Discovery 0000000 0
You’re viewing 5 of 15 investments and acquisitions. Get the full list »

Vertex Pharmaceuticals Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 07-Sep-2016 00000 00000 00 00000 Completed
  • 2 buyers
Altus Pharmaceuticals 06-Mar-2007 PIPE 0000 Completed
  • 3 buyers
To view Vertex Pharmaceuticals’s complete exits history, request access »